Promising Efficacy and Safety With Seleno-L-Methionine Plus Axitinib in ccRCC

Yousef Zakharia, MD, associate professor of medicine, University of Iowa, Holden Comprehensive Cancer Center, discussed recent phase I data from a study of seleno-L-methionine (SLM) in combination with axitinib (Inlyta) as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC). Zakharia recently presented these data as part of the American Urological Association (AUA) Virtual Experience platform for the 2020 AUA Annual Meeting.

Out of 15 evaluable patients with ccRCC who progressed on one or more prior lines of treatment, responses were seen across all cohorts of patients who received SLM in combination with axitinib. Overall responses were seen in 53% of patients (n = 8). Complete responses (CRs) were observed in 2 patients. CRs for these patients were still ongoing at 31 and 29 months, respectively. Partial responses were observed in 6 patients, with a disease control rate of about 73%. Some responses lasted for more than 3 years.

There were no dose-limiting toxicities in the study. Most commonly, adverse events (AEs) were grades 1 and 2.The most common AEs that patients experienced were fatigue, diarrhea, hypertension, nausea, anorexia, cough, proteinuria, and weight loss. The most common grade 3 or 4 AE was hypertension. These AEs were consistent with the known toxicity of axitinib. No grade 4 and 5 toxicities were observed.